Roadmap2Rare and other initiatives:
Sanofi Canada is working towards the launch of several Electronic Medical Record screening initiatives in Canada that will offer clinicians the option to scan records for patients who are at high risk of having a rare disease.
In collaboration with PerkinElmer Genomics, Sanofi Canada has launched the Roadmap2Rare Diagnostic Program, a sponsored testing program that covers enzymatic activity, biomarker, and genetic testing for several rare diseases. The program also provides access to multi-gene panels that include common differential diagnoses for Pompe and Fabry disease. Metabolic genotyping for Gaucher disease type 1 (when applicable to certain treatment considerations) is available separately in collaboration with ARCHIMEDlife.
Treatment and Monitoring
After a rare disease diagnosis, clinicians may wish to monitor disease progression and treatment response. Sanofi provides access to biomarker monitoring for several rare diseases through a sponsored, international Rare Disease Specialty Testing Program.
This program also covers immunogenicity testing for patients on Sanofi treatment, including complimentary analysis of anti-drug antibody levels and adverse event-related testing.
To support rare disease patients on treatment with Sanofi products and their treating clinicians, Sanofi Canada offers the Rare Together Patient Support Program. This program is tailored to each patient, helps address barriers to access, and supports the administration of drugs for complex medical conditions.
Sanofi sponsors services and tools that are available at no charge, to support Canadian patients and clinicians along the rare disease journey. For clinicians with questions about any of these programs, get in touch!